Want to see AU:PAR full AI Analyst Report?

Paradigm Biopharmaceuticals (PAR) Price & Analysis

43 Followers

PAR Stock Chart & Stats

AU$0.33

-AU$0.03(-5.32%)

At close: Jan 09 4:00 PM EST

AU$0.33

-AU$0.03(-5.32%)

Day’s Range― - ―

52-Week RangeAU$0.14 - AU$0.47

Previous CloseN/A

Volume3.26M

Average Volume (3M)841.61K

Market Cap

AU$93.57M

Enterprise ValueAU$68.69M

Total Cash (Recent Filing)AU$14.66M

Total Debt (Recent Filing)AU$1.01M

Price to Earnings (P/E)―

Beta2.54

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding584,843,570

10 Day Avg. Volume720,106

30 Day Avg. Volume841,610

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.45

Price Target Upside36.36% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.1

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageA conservatively levered balance sheet reduces refinancing and interest-rate risk for a cash-burning biotech. Low debt preserves capacity to raise capital via equity or partnerships, supporting long-term investment in trials, approvals and commercialization without immediate solvency pressure.

Improving Cash OutflowA marked reduction in operating cash outflows signals improving cost discipline or operational efficiency. If sustained, lower burn extends runway, reduces near-term funding needs and increases chances that business milestones can be reached before dilutive financing is required.

Commercialization-based Revenue ModelA core revenue model built on prescription product sales, plus licensing and distribution partnerships, provides multiple scalable commercial paths. This mix can generate recurring sales and non-dilutive milestone or royalty income as products gain market traction.

Bears Say

Persistent Negative Cash FlowOngoing negative operating and free cash flow indicates the business cannot self-fund operations or growth. Reliance on external capital is likely to persist, increasing dilution risk and constraining long-term R&D, regulatory and commercial investments if funding conditions tighten.

Small, Volatile RevenueA tiny and inconsistent revenue base limits ability to achieve scale, absorb fixed costs, or generate sustainable margins. Volatility makes forecasting, pricing leverage and reinvestment planning difficult, prolonging the timeline to profitability and commercial stability.

Declining Equity & Negative ROEMaterial equity erosion and persistently negative ROE reflect continuing value destruction from losses. This weakens the capital base, can increase cost of capital, and complicates fundraising or partnership negotiations needed to finance ongoing development and commercialization.

Paradigm Biopharmaceuticals News

Paradigm Biopharmaceuticals issues cleansing notice for latest US$3m convertible notes

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has issued a cleansing notice covering a...

4d ago

Paradigm Biopharmaceuticals Issues 3 Million Unquoted Convertible Notes

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has notified the market of...

4d ago

Paradigm Secures Fresh Funds to Advance Phase 3 Knee Osteoarthritis Trial

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has drawn down Tranche 4...

4d ago

Paradigm Biopharmaceuticals updates market on director’s shareholding change

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in...

16d ago

Paradigm Biopharmaceuticals Cancels 939,500 Lapsed Performance Rights

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has reported the lapse of 939,500 performance...

18d ago

Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has cancelled 1,795,000 ordinary fully paid shares...

18d ago

Paradigm Biopharmaceuticals Updates Director Matthew Fry’s Option Holdings

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in...

29d ago

Paradigm Biopharmaceuticals updates market on director Paul Rennie’s expanded option holdings

An announcement from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has reported a change in...

29d ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Over 10 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has applied for the quotation of 10,139,313...

29d ago

Paradigm Biopharmaceuticals’ Top 20 Option Holders Control Majority of PAROPTWC Register

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has released an updated top holders report...

1M ago

PAR FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.14 and its highest was AU$0.47 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is AU$93.57M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 35 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.056.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 584,843,570 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:PAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-265.55%

Trailing 12-Months

Asset Growth

-29.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.

Paradigm Biopharmaceuticals (PAR) Earnings & Revenues

Historic Earnings Reports

PAR Stock 12 Month Forecast

Average Price Target

AU$0.45

▲(36.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.18,0.20076923076923076,0.22153846153846152,0.2423076923076923,0.2630769230769231,0.28384615384615386,0.3046153846153846,0.3253846153846154,0.34615384615384615,0.3669230769230769,0.38769230769230767,0.40846153846153843,0.4292307692307692,{"y":0.45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.18,0.20076923076923076,0.22153846153846152,0.2423076923076923,0.2630769230769231,0.28384615384615386,0.3046153846153846,0.3253846153846154,0.34615384615384615,0.3669230769230769,0.38769230769230767,0.40846153846153843,0.4292307692307692,{"y":0.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.18,0.20076923076923076,0.22153846153846152,0.2423076923076923,0.2630769230769231,0.28384615384615386,0.3046153846153846,0.3253846153846154,0.34615384615384615,0.3669230769230769,0.38769230769230767,0.40846153846153843,0.4292307692307692,{"y":0.45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.375,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.345,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.335,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.425,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.295,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.255,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.16,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.155,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >